Evidence map›Paper›PMID 39519404›Full record

ArticleInternational journal of molecular sciences2024

Ecto-NOX Disulfide-Thiol Exchanger 2 (ENOX2/tNOX) Is a Potential Prognostic Marker in Primary Malignant Melanoma and May Serve as a Therapeutic Target.

Matti Böcker, Eftychia Chatziioannou, Heike Niessner, Constanze Hirn, Christian Busch, Kristian Ikenberg, Hubert Kalbacher, Rupert Handgretinger, Tobias Sinnberg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Alanyl-Glutamine Dipeptide MitigatesInternational journal of molecular sciences · 2026
    Article
  2. Article
  3. Review
  4. Advances in Pathogenesis and Treatment of Skin Cancer.International journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Matti BöckerDivision of Dermatooncology, Department of Dermatology, University of Tuebingen, Liebermeisterstraße 25, 72076 Tuebingen, Germany.
Eftychia ChatziioannouDivision of Dermatooncology, Department of Dermatology, University of Tuebingen, Liebermeisterstraße 25, 72076 Tuebingen, Germany.ORCID 0000-0002-7843-7160
Heike NiessnerDivision of Dermatooncology, Department of Dermatology, University of Tuebingen, Liebermeisterstraße 25, 72076 Tuebingen, Germany.ORCID 0000-0002-2542-7022
Constanze HirnDivision of Dermatooncology, Department of Dermatology, University of Tuebingen, Liebermeisterstraße 25, 72076 Tuebingen, Germany.
Christian BuschDermatologie zum Delfin, Stadthausstraße 12, 8400 Winterthur, Switzerland.
Kristian IkenbergInstitute of Clinical Pathology, University Hospital Zuerich, Schmelzbergstraße 12, 8091 Zuerich, Switzerland.
Hubert KalbacherInstitute of Clinical Anatomy and Cell Analysis, University of Tuebingen, Elfriede-Aulhorn-Straße 8, 72076 Tuebingen, Germany.
Rupert HandgretingerDepartment of General Pediatrics, Hematology and Oncology, University Children's Hospital Tuebingen, Hoppe-Seyler-Straße 1, 72076 Tuebingen, Germany.ORCID 0000-0003-1838-8990
Tobias SinnbergDivision of Dermatooncology, Department of Dermatology, University of Tuebingen, Liebermeisterstraße 25, 72076 Tuebingen, Germany.ORCID 0000-0003-3922-3327

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With an increasing incidence of malignant melanoma, new prognostic biomarkers for clinical decision making have become more important. In this study, we evaluated the role of ecto-NOX disulfide-thiol exchanger 2 (ENOX2/tNOX), a cancer- and growth-associated protein, in the prognosis and therapy of primary malignant melanoma. We conducted a tissue microarray analysis of immunohistochemical ENOX2 protein expression and The Cancer Genome Atlas (TCGA)

Indexed as

Biomarkers, TumorMelanomaAgedCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisSkin NeoplasmsVemurafenibBiomarkers, TumorVemurafenibbiomarkerecto-NOX disulfide-thiol exchanger 2ENOX2malignant melanomaphenoxodioltNOXvemurafenib

Identifiers

PMID39519404
PMCPMC11545956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.